September 17, 2021
Article
A presentation at the Society of Hematologic Oncology 2021 Annual Meeting reviewed the treatment of amyloidosis in multiple myeloma.
Video
Shereen Stutz and Mark Alwardt, of McKesson, said the rise in oral oncolytics during the COVID-19 pandemic allowed pharmacists to be more innovative and to become an even more integrated part of the oncology care team.
September 16, 2021
Patients now have multiple options, including continuous therapy with BTK inhibitors and fixed-duration therapy with venetoclax-based regimens.
September 15, 2021
Presenter Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca-IBSAL, Salamanca, Spain, discussed how optimal sequencing in MM has changed from those outlined in the older EU guidelines.
In the MAGNOLIA trial, the median duration of response was not reached at the median follow-up time of 8.3 months, with 85% of responders still in remission at 12 months.
Cabozantinib (Cabometyx) was approved in 2016 for patients who have advanced renal cell carcinoma and who received prior anti-angiogenic therapy.
September 10, 2021
With CAR T-cell therapies showing promise for follicular lymphoma and marginal zone lymphoma, clinicians must weigh toxicity and tolerability almost as strongly as efficacy because patients can live years with these diseases
September 09, 2021
The efficacy of pirtobrutinib does not depend on prior therapy, reason for prior BTK inhibitor discontinuation, or C481 mutation status, according to the presentation.
Because asparaginase is used exclusively in ALL, most adult oncologists do not administer it routinely.
September 08, 2021
Nearly 20% of patients with multiple myeloma have a form of the disease in which they make high quantities of a component of monoclonal proteins, which damages the kidneys.
